Table 1.

Emerging Therapeutic Possibilities in Extranodal NK/T-cell Lymphoma.

Pathway	Therapeutic	References
JAK/STAT	Tofacitinib (JAK inhibitor)/PRN371 (JAK3 selective inhibitor)/Stattic (STAT3 inhibitor)	[44,45,46]
EZH2	3-deazaneplanocin A (EZH2 inhibitor)	[29,44]
NF-κB	Bortezomib	[47]
PD-1	Pembrolizumab	[28,48]
CD30	Brentuximab	[49]
LMP-1	LMP1/2a-specific CTL	[51]
Survivin	Terameprocol	[15,52]